Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its price objective raised by equities researchers at Robert W. Baird to $40.00 in a report released on Tuesday, Stock Target Advisor reports. Robert W. Baird’s target price points to a potential upside of 5.04% from the company’s previous close.
Several other research analysts have also recently issued reports on RETA. StockNews.com began coverage on Reata Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “sell” rating for the company. Guggenheim began coverage on Reata Pharmaceuticals in a research note on Wednesday, October 19th. They issued a “buy” rating and a $75.00 price target for the company. Barclays increased their price target on Reata Pharmaceuticals from $43.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 9th. Citigroup upped their price objective on Reata Pharmaceuticals from $51.00 to $53.00 and gave the company a “buy” rating in a report on Wednesday, November 9th. Finally, The Goldman Sachs Group upped their price objective on Reata Pharmaceuticals from $76.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, November 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.75.
Reata Pharmaceuticals Price Performance
Shares of RETA opened at $38.08 on Tuesday. The company has a market cap of $1.39 billion, a P/E ratio of -4.45 and a beta of 1.15. The stock has a fifty day moving average price of $30.07 and a 200 day moving average price of $29.13. Reata Pharmaceuticals has a 12 month low of $18.47 and a 12 month high of $95.37.
Institutional Investors Weigh In On Reata Pharmaceuticals
Several hedge funds have recently modified their holdings of RETA. DekaBank Deutsche Girozentrale lifted its holdings in shares of Reata Pharmaceuticals by 9.9% during the first quarter. DekaBank Deutsche Girozentrale now owns 16,640 shares of the company’s stock valued at $514,000 after purchasing an additional 1,500 shares during the last quarter. Keybank National Association OH purchased a new stake in shares of Reata Pharmaceuticals during the first quarter valued at $500,000. Arizona State Retirement System purchased a new stake in shares of Reata Pharmaceuticals during the first quarter valued at $237,000. Quadrant Capital Group LLC lifted its holdings in shares of Reata Pharmaceuticals by 29.2% during the first quarter. Quadrant Capital Group LLC now owns 25,882 shares of the company’s stock valued at $848,000 after purchasing an additional 5,856 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in shares of Reata Pharmaceuticals by 7.5% during the first quarter. Swiss National Bank now owns 63,300 shares of the company’s stock valued at $2,074,000 after purchasing an additional 4,400 shares during the last quarter. 76.00% of the stock is owned by hedge funds and other institutional investors.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.
- Get a free copy of the StockNews.com research report on Reata Pharmaceuticals (RETA)
- International Game Technology is Well Worth the Gamble
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Use The Airbnb Stock Implosion to Your Advantage
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.